DNTH
Dianthus Therapeutics, Inc. /DE/
$78.88
-4.40%
$4.3B
No data for this timeframe.
Vol
Market Cap$4.3B
Cap SizeMid Cap
Analyst ConsensusStrong Buy (95%)
Inst. Holders50 funds
Inst. Value$2.9B
Inst. Activity36 buys / 9 sells
Insider Activity0B / 9S
Insider Net $-$11.1M
SEC Reports6
Press Releases4
Recent Activity
Jun 12, 2026
SEC
Dianthus Therapeutics posted an updated corporate presentation disclosing a 75% confirmed responder rate from the first
8-K — Impact 7/10
Jun 11, 2026
SEC
Five institutional investors (including two hedge funds with strong alpha track records — Citadel and Point72) added $23
INST-CLUSTER — Impact 5/10
Jun 2, 2026
other
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p>NEW YORK and WALTHAM, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nas
Jun 1, 2026
Insider
Randhawa Simrat acquired via exercise 3,998 shares
EVP, Head of R&D @ $8.44 ($33.7K)
Jun 1, 2026
Insider
Randhawa Simrat sold 5,428 shares
EVP, Head of R&D @ $89.72 ($487.0K)
May 21, 2026
Insider
KANGO SUJAY was granted 6,090 shares
Director
May 5, 2026
SEC
Dianthus Therapeutics reported Q1 2026 net loss of $40.8M ($0.85/share) and highlighted major pipeline progress: early G
8-K — Impact 7/10
Inst.
BlackRock, Inc. — ADD
3,175,703 shares ($266.5M)
Price Targets
$127.67
+61.8% upside
Strong Buy
Current $78.88
Low $98.00
Median $125.00
High $200.00
12 analysts
$98.00
$200.00
Analyst Ratings
10Strong Buy
11Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 6, 2026 | Wedbush | MAINTAIN | Outperform → Outperform |
| Apr 9, 2026 | Wolfe Research | INITIATE | Outperform |
| Mar 19, 2026 | Wells Fargo | INITIATE | Overweight |
| Mar 12, 2026 | Wedbush | MAINTAIN | Outperform → Outperform |
| Mar 10, 2026 | Wedbush | MAINTAIN | Outperform → Outperform |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.91 | $-1.23 — $-0.72 | -3% YoY | 8 |
| Next Q | $-1.02 | $-1.43 — $-0.85 | -5% YoY | 8 |
| Current FY | $-3.93 ▼ -0.7% | $-5.06 — $-3.44 | 7% YoY | 9 |
| Next FY | $-4.65 ▼ -0.5% | $-5.70 — $-3.69 | -18% YoY | 9 |
Latest Reports
BULLISH
8-K
7/10
Dianthus Therapeutics posted an updated corporate presentation disclosing a 75% confirmed responder rate from the first
Jun 12, 2026
BULLISH
INST-CLUSTER
5/10
Five institutional investors (including two hedge funds with strong alpha track records — Citadel and Point72) added $23
Jun 11, 2026
NEUTRAL
Press
6/10
Dianthus Therapeutics raised approximately $719 million in gross proceeds through a public offering of 8.47 million comm
Mar 12, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| FMR LLC | $651.9M | — |
| BlackRock, Inc. | $266.5M | ADD |
| RA CAPITAL MANAGEMENT, L.P. | $219.2M | ADD |
| WELLINGTON MANAGEMENT GROUP LLP | $217.8M | — |
| VANGUARD CAPITAL MANAGEMENT LLC | $170.5M | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 1, 2026 | Randhawa Simrat | M | $33.7K |
| Jun 1, 2026 | Randhawa Simrat | SELL | $487.0K |
| May 21, 2026 | KANGO SUJAY | A | $0.00 |
| May 21, 2026 | Violin Jonathan | A | $0.00 |
| May 21, 2026 | McGeorge Anne | A | $0.00 |
50 institutional holders with $2.9B total value (35,295,836 shares) as of 2026-Q1. Top holders: FMR, BlackRock,, RA. Net buying activity: 36 institutions added/increased vs 9 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | FMR LLC | 7,767,686 | $651.9M | 22.3% | — |
| 2 | BlackRock, Inc. | 3,175,703 | $266.5M | 9.1% | ADD +65.8% |
| 3 | RA CAPITAL MANAGEMENT, L.P. | 2,611,733 | $219.2M | 7.5% | ADD +62.0% |
| 4 | WELLINGTON MANAGEMENT GROUP LLP | 2,595,783 | $217.8M | 7.5% | — |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 2,031,249 | $170.5M | 5.8% | — |
| 6 | CITADEL ADVISORS LLC | 1,610,483 | $135.2M | 4.6% | — |
| 7 | STATE STREET CORP | 1,398,913 | $117.4M | 4.0% | DOUBLED +124.7% |
| 8 | FRED ALGER MANAGEMENT, LLC | 1,161,923 | $97.5M | 3.3% | DOUBLED +3372.6% |
| 9 | Polar Capital Holdings Plc | 1,076,009 | $90.3M | 3.1% | — |
| 10 | FRANKLIN RESOURCES INC | 968,182 | $81.2M | 2.8% | DOUBLED +109.2% |
| 11 | BAKER BROS. ADVISORS LP | 852,164 | $71.5M | 2.4% | — |
| 12 | FARALLON CAPITAL MANAGEMENT LLC | 836,000 | $70.2M | 2.4% | NEW |
| 13 | Point72 Asset Management, L.P. | 643,599 | $54.0M | 1.8% | TRIM -44.8% |
| 14 | GOLDMAN SACHS GROUP INC | 548,010 | $46.0M | 1.6% | — |
| 15 | JENNISON ASSOCIATES LLC | 485,136 | $40.7M | 1.4% | NEW |
| 16 | BALYASNY ASSET MANAGEMENT L.P. | 474,085 | $39.8M | 1.4% | NEW |
| 17 | ALLIANCEBERNSTEIN L.P. | 926,071 | $38.2M | 1.3% | — |
| 18 | Woodline Partners LP | 433,457 | $36.4M | 1.2% | DOUBLED +103.4% |
| 19 | Artisan Partners Limited Partnership | 382,121 | $32.1M | 1.1% | NEW |
| 20 | BARCLAYS PLC | 379,606 | $31.9M | 1.1% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| BlackRock, Inc. | ADD | 1,915,236 | 3,175,703 | +65.8% | $266.5M | 2026-Q1 |
| RA CAPITAL MANAGEMENT, L.P. | ADD | 1,611,733 | 2,611,733 | +62.0% | $219.2M | 2026-Q1 |
| FRED ALGER MANAGEMENT, LLC | DOUBLED | 33,460 | 1,161,923 | +3372.6% | $97.5M | 2026-Q1 |
| FRANKLIN RESOURCES INC | DOUBLED | 462,826 | 968,182 | +109.2% | $81.2M | 2026-Q1 |
| FARALLON CAPITAL MANAGEMENT LLC | NEW | — | 836,000 | — | $70.2M | 2026-Q1 |
| Point72 Asset Management, L.P. | TRIM | 1,166,088 | 643,599 | -44.8% | $54.0M | 2026-Q1 |
| JENNISON ASSOCIATES LLC | NEW | — | 485,136 | — | $40.7M | 2026-Q1 |
| BALYASNY ASSET MANAGEMENT L.P. | NEW | — | 474,085 | — | $39.8M | 2026-Q1 |
| Woodline Partners LP | DOUBLED | 213,087 | 433,457 | +103.4% | $36.4M | 2026-Q1 |
| Artisan Partners Limited Partnership | NEW | — | 382,121 | — | $32.1M | 2026-Q1 |
| AMERIPRISE FINANCIAL INC | DOUBLED | 155,163 | 358,470 | +131.0% | $30.1M | 2026-Q1 |
| MARSHALL WACE, LLP | TRIM | 1,008,533 | 341,929 | -66.1% | $28.7M | 2026-Q1 |
| DIMENSIONAL FUND ADVISORS LP | ADD | 210,673 | 325,440 | +54.5% | $27.3M | 2026-Q1 |
| DRIEHAUS CAPITAL MANAGEMENT LLC | NEW | — | 317,312 | — | $26.6M | 2026-Q1 |
| RTW INVESTMENTS, LP | NEW | — | 248,063 | — | $20.8M | 2026-Q1 |
| Freestone Grove Partners LP | NEW | — | 239,943 | — | $20.1M | 2026-Q1 |
| BANK OF AMERICA CORP /DE/ | TRIM | 465,538 | 188,779 | -59.4% | $15.8M | 2026-Q1 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | NEW | — | 160,000 | — | $13.4M | 2026-Q1 |
| Invesco Ltd. | ADD | 101,489 | 130,747 | +28.8% | $11.0M | 2026-Q1 |
| Russell Investments Group, Ltd. | ADD | 88,289 | 129,065 | +46.2% | $10.8M | 2026-Q1 |
| TD ASSET MANAGEMENT INC | DOUBLED | 31,750 | 116,576 | +267.2% | $9.8M | 2026-Q1 |
| MORGAN STANLEY | TRIM | 228,016 | 97,455 | -57.3% | $8.2M | 2026-Q1 |
| SEI INVESTMENTS CO | DOUBLED | 13,841 | 92,229 | +566.3% | $7.7M | 2026-Q1 |
| ExodusPoint Capital Management, LP | TRIM | 246,788 | 85,530 | -65.3% | $7.2M | 2026-Q1 |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | DOUBLED | 25,598 | 65,238 | +154.9% | $5.5M | 2026-Q1 |
12 unique insiders with 31 transactions. Net insider value: -$11.1M ($0.00 bought, $11.1M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 1, 2026 | Randhawa Simrat | EVP, Head of R&D | EXERCISE | 3,998 | $8.44 | $33.7K |
| Jun 1, 2026 | Randhawa Simrat | EVP, Head of R&D | SELL | 5,428 | $89.72 | $487.0K |
| May 21, 2026 | KANGO SUJAY | Director | AWARD | 6,090 | — | — |
| May 21, 2026 | Violin Jonathan | Director | AWARD | 6,090 | — | — |
| May 21, 2026 | McGeorge Anne | Director | AWARD | 6,090 | — | — |
| May 21, 2026 | Soteropoulos Paula | Director | AWARD | 6,090 | — | — |
| May 21, 2026 | Read Simon | Director | AWARD | 6,090 | — | — |
| May 21, 2026 | Romano Steven J. | Director | AWARD | 6,090 | — | — |
| May 21, 2026 | Lawton Alison Frances | Director | AWARD | 6,090 | — | — |
| May 8, 2026 | Soteropoulos Paula | Director | EXERCISE | 599 | $8.44 | $5.1K |
| May 8, 2026 | Soteropoulos Paula | Director | SELL | 599 | $85.47 | $51.2K |
| Apr 9, 2026 | Savitz Ryan | EVP, CFO & CBO | EXERCISE | 8,224 | $17.88 | $147.0K |
| Apr 9, 2026 | Savitz Ryan | EVP, CFO & CBO | SELL | 8,224 | $89.84 | $738.8K |
| Mar 31, 2026 | Soteropoulos Paula | Director | EXERCISE | 599 | $8.44 | $5.1K |
| Mar 31, 2026 | Soteropoulos Paula | Director | SELL | 599 | $80.11 | $48.0K |
| Mar 31, 2026 | Savitz Ryan | EVP, CFO & CBO | EXERCISE | 74,367 | $8.44 | $627.7K |
| Mar 31, 2026 | Savitz Ryan | EVP, CFO & CBO | SELL | 1,390 | $78.33 | $108.9K |
| Mar 24, 2026 | Soteropoulos Paula | Director | EXERCISE | 27,594 | $8.44 | $232.9K |
| Mar 24, 2026 | Soteropoulos Paula | Director | SELL | 27,594 | $78.05 | $2.2M |
| Mar 16, 2026 | Garcia Marino | CEO AND PRESIDENT | EXERCISE | 59,700 | $6.70 | $400.0K |
| Mar 12, 2026 | Garcia Marino | CEO AND PRESIDENT | SELL | 43,505 | $80.69 | $3.5M |
| Mar 12, 2026 | Garcia Marino | CEO AND PRESIDENT | EXERCISE | 122,918 | $6.70 | $823.6K |
| Mar 12, 2026 | CARR EDWARD | CHIEF ACCOUNTING OFFICER | EXERCISE | 16,182 | $17.88 | $289.3K |
| Mar 12, 2026 | CARR EDWARD | CHIEF ACCOUNTING OFFICER | SELL | 15,852 | $80.71 | $1.3M |
| Mar 12, 2026 | Randhawa Simrat | EVP, Head of R&D | SELL | 33,830 | $81.48 | $2.8M |
| Mar 12, 2026 | Randhawa Simrat | EVP, Head of R&D | EXERCISE | 7,998 | $8.44 | $67.5K |
| Feb 3, 2026 | Garcia Marino | CEO AND PRESIDENT | AWARD | 355,000 | — | — |
| Feb 3, 2026 | Savitz Ryan | EVP, CFO & CBO | AWARD | 150,000 | — | — |
| Feb 3, 2026 | Veness Adam M | SVP, General Counsel and Sec. | AWARD | 100,000 | — | — |
| Feb 3, 2026 | CARR EDWARD | CHIEF ACCOUNTING OFFICER | AWARD | 55,000 | — | — |
| Feb 3, 2026 | Randhawa Simrat | EVP, Head of R&D | AWARD | 150,000 | — | — |
6 SEC filing reports analyzed. Sentiment: 3 bullish, 2 bearish, 0 mixed, 1 neutral. Avg impact: 6.0/10.
BULLISH
8-K
7/10
Dianthus Therapeutics posted an updated corporate presentation disclosing a 75% confirmed responder
Jun 12, 2026
BULLISH
INST-CLUSTER
5/10
Five institutional investors (including two hedge funds with strong alpha track records — Citadel an
Jun 11, 2026
BULLISH
8-K
7/10
Dianthus Therapeutics reported Q1 2026 net loss of $40.8M ($0.85/share) and highlighted major pipeli
May 5, 2026
BEARISH
CLUSTER
7/10
Dianthus Therapeutics CEO, R&D head, and CFO-equivalent executed a coordinated cluster of derivative
Mar 17, 2026
BEARISH
CLUSTER
7/10
Three Dianthus Therapeutics executives, including the CEO and EVP of R&D, exercised stock options an
Mar 14, 2026
NEUTRAL
8-K
3/10
Analysis based on filing metadata only — document content was unavailable. The filing is an 8-K with
Mar 12, 2026
NEUTRAL
6/10
Dianthus Therapeutics raised approximately $719 million in gross proceeds through a public offering
Mar 12, 2026
NEUTRAL
6/10
Dianthus Therapeutics priced an upsized public offering of 7,313,582 shares at $81.00 per share and
Mar 11, 2026
BULLISH
8/10
Dianthus Therapeutics reported full-year 2025 financial results and announced a positive GO decision
Mar 9, 2026
NEUTRAL
5/10
Dianthus Therapeutics announced a conference call to discuss interim responder analysis results from
Mar 8, 2026
Current analyst consensus: Strong Buy (95% buy). Based on 22 analysts: 10 strong buy, 11 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$127.67 mean target
+61.8% upside
Strong Buy (1.00)
$98.00 Low
$200.00 High
| Metric | Value |
|---|---|
| Current Price | $78.88 |
| Target Low | $98.00 |
| Target Mean | $127.67 |
| Target Median | $125.00 |
| Target High | $200.00 |
| # Analysts | 12 |
| Recommendation | Strong Buy (1.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.91 | $-1.23 | $-0.72 | -3.3% | +0.0% | 1↑ 0↓ | $0.0B | 28.9% | 8 |
| Next Q 2026-09-30 |
$-1.02 | $-1.43 | $-0.85 | -5.4% | +0.0% | 1↑ 0↓ | $0.0B | -34.1% | 8 |
| Current FY 2026-12-31 |
$-3.93 | $-5.06 | $-3.44 | 6.5% | -0.7% | 5↑ 1↓ | $0.0B | -40.6% | 9 |
| Next FY 2027-12-31 |
$-4.65 | $-5.70 | $-3.69 | -18.5% | -0.5% | 5↑ 1↓ | $0.0B | 31.1% | 9 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.909 | |
| 7d ago | $-0.909 | |
| 30d ago | $-0.909 | |
| 60d ago | $-1.111 | +0.203 |
| 90d ago | $-1.113 | +0.205 |
11 analyst firms have rated this stock: 1 upgrades, 0 downgrades, 2 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 6, 2026 | Wedbush | MAINTAIN | Outperform | Outperform |
| Apr 9, 2026 | Wolfe Research | INITIATE | — | Outperform |
| Mar 19, 2026 | Wells Fargo | INITIATE | — | Overweight |
| Mar 12, 2026 | Wedbush | MAINTAIN | Outperform | Outperform |
| Mar 10, 2026 | Wedbush | MAINTAIN | Outperform | Outperform |
| Mar 10, 2026 | Raymond James | UPGRADE | Outperform | Strong Buy |
| Mar 10, 2026 | Baird | MAINTAIN | Outperform | Outperform |
| Mar 10, 2026 | Clear Street | MAINTAIN | Buy | Buy |
| Mar 9, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Mar 9, 2026 | Oppenheimer | MAINTAIN | Outperform | Outperform |
| Mar 9, 2026 | Truist Securities | MAINTAIN | Buy | Buy |
| Mar 4, 2026 | Guggenheim | MAINTAIN | Buy | Buy |
| Feb 11, 2026 | Wedbush | MAINTAIN | Outperform | Outperform |
| Feb 2, 2026 | Jefferies | MAINTAIN | Buy | Buy |
| Jan 8, 2026 | Truist Securities | MAINTAIN | Buy | Buy |
| Dec 22, 2025 | Wedbush | REITERATE | Outperform | Outperform |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 10 | 11 | 1 | 0 | 0 | 95% | |
| May 1, 2026 | 11 | 11 | 1 | 0 | 0 | 96% | |
| Apr 1, 2026 | 10 | 11 | 1 | 0 | 0 | 95% | |
| Mar 1, 2026 | 9 | 11 | 1 | 0 | 0 | 95% | |
| Feb 1, 2026 | 9 | 11 | 1 | 0 | 0 | 95% | |
| Jan 1, 2026 | 9 | 11 | 1 | 0 | 0 | 95% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 2, 2026
other
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p>NEW YORK and WALTHAM, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company
May 26, 2026
other
Dianthus Therapeutics to Participate in Two Investor Conferences
<p>NEW YORK and WALTHAM, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company
May 20, 2026
ftd
FTD: DNTH — 13,995 shares ($1.2M) failed to deliver
Settlement: 20260520, Price: $85.67, FTD Value: $1,198,951.65, DIANTHUS THERAPEUTICS INC COM
May 11, 2026
earnings_calendar
DNTH Q1 2026 Earnings Scheduled — 2026-05-11
May 7, 2026
earnings_calendar
DNTH Q1 2026 Earnings Scheduled — 2026-05-07
May 5, 2026
earnings
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 2026 Financial Results
<p align="center"><em>Early GO decision reached in CAPTIVATE in March 2026 based on GO criteria of 20 confirmed responders achieved with less than 40
May 1, 2026
other
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p>NEW YORK and WALTHAM, Mass., May 01, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company
Apr 6, 2026
activist
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p>NEW YORK and WALTHAM, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology compan
Mar 26, 2026
short_interest
FTD: DNTH — 21,205 shares ($1.7M) failed to deliver
Settlement: 20260326, Price: $79.61, FTD Value: $1,688,130.05, DIANTHUS THERAPEUTICS INC COM
Mar 12, 2026
offering
Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
<p>NEW YORK and WALTHAM, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH) (“Dianthus” or the “Company”), a clini
Mar 11, 2026
offering
Dianthus Therapeutics, Inc. Announces Pricing of Upsized $625 Million Underwritten Public Offering
<p>NEW YORK and WALTHAM, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH) (“Dianthus” or the “Company”), a clini
Mar 9, 2026
offering
Dianthus Therapeutics, Inc. Announces Proposed $400 Million Underwritten Public Offering
<p>NEW YORK and WALTHAM, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH) (“Dianthus” or the “Company”), a clini
Mar 9, 2026
earnings
Dianthus Therapeutics Highlights Recent Business Achievements, Including GO Decision for Phase 3 CAPTIVATE CIDP Trial, and Reports Q4 and FY 2025 Financial Results
<p align="center"><em>Early GO decision reached in CAPTIVATE ahead of Q2’26 guidance based on GO criteria of 20 confirmed responders achieved with les
Mar 9, 2026
earnings
Dianthus Therapeutics Announces Early GO Decision Following Interim Responder Analysis in Phase 3 CAPTIVATE Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
<p align="center"><em>Early GO decision reached ahead of Q2’26 guidance based on GO criteria of 20 confirmed responders achieved with less than 40 pla
Mar 9, 2026
earnings_calendar
DNTH Q4 2025 Earnings After Market Close — 2026-03-09